Literature DB >> 8214945

Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis.

M W Konstan1, R W Walenga, K A Hilliard, J B Hilliard.   

Abstract

Persistent neutrophil infiltration into the airways of patients with cystic fibrosis (CF) results in lung destruction. Eicosanoid lipid mediators, particularly leukotriene B4 (LTB4), may play a role in neutrophil influx and activation. We compared the eicosanoid content of epithelial lining fluid (ELF) obtained by bronchoalveolar lavage (BAL) from 17 patients with CF and 10 healthy subjects. LTB4 was the predominant eicosanoid in the CF airway (16.7 +/- 9.1 ng/ml ELF in CF versus 0.5 +/- 0.1 ng/ml ELF in healthy subjects). Prostaglandins (PG) and thromboxane (TX) were also elevated in CF (PGE2, 8.5 +/- 2.2; PGF2 alpha, 6.0 +/- 2.0; and TXB2, 14.0 +/- 3.0 ng/ml ELF) compared with healthy subjects (PGE2, 0.4 +/- 0.2; PGF2 alpha, 0.5 +/- 0.2; and TXB2, 1.2 +/- 0.4 ng/ml ELF). We also developed a protocol for the storage and subsequent analysis of BAL fluid that assures accurate and reproducible measurements of these eicosanoids. BAL samples stored for up to 8 months retain greater than 80% of their original eicosanoid content if the BAL fluid is immediately treated with methanol, concentrated, and stored at -70 degrees C without further purification. These data suggest that CF airways contain sufficient amounts of LTB4 both to recruit additional neutrophils into the airways and to stimulate neutrophils to release their injurious products. Therapies aimed at interfering with the production or action of LTB4 may be beneficial in CF and other lung diseases with a significant neutrophil response.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8214945     DOI: 10.1164/ajrccm/148.4_Pt_1.896

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  41 in total

Review 1.  Pulmonary diseases other than asthma as potential targets for antileukotriene therapy.

Authors:  M Peters-Golden
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  The measurement of leukotrienes in human fluids.

Authors:  J Y Westcott
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

3.  Do inhaled corticosteroids impair long-term growth in prepubertal cystic fibrosis patients?

Authors:  Kris De Boeck; Frans De Baets; Anne Malfroot; Kristine Desager; Françoise Mouchet; Marijke Proesmans
Journal:  Eur J Pediatr       Date:  2006-06-24       Impact factor: 3.183

Review 4.  Role of corticosteroids in cystic fibrosis lung disease.

Authors:  I M Balfour-Lynn; R Dinwiddie
Journal:  J R Soc Med       Date:  1996       Impact factor: 5.344

5.  A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis.

Authors:  M W Konstan; G Döring; S L Heltshe; L C Lands; K A Hilliard; P Koker; S Bhattacharya; A Staab; A Hamilton
Journal:  J Cyst Fibros       Date:  2014-01-17       Impact factor: 5.482

Review 6.  Treatment of severe small airways disease in children with cystic fibrosis: alternatives to corticosteroids.

Authors:  Adam Jaffe; Ian M Balfour-Lynn
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 7.  The role of inflammation in the pathophysiology of CF lung disease.

Authors:  James F Chmiel; Melvin Berger; Michael W Konstan
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

8.  Eicosanoid release is increased by membrane destabilization and CFTR inhibition in Calu-3 cells.

Authors:  Florence Borot; Diane-Lore Vieu; Grazyna Faure; Janine Fritsch; Julien Colas; Sandra Moriceau; Maryvonne Baudouin-Legros; Franck Brouillard; Jesus Ayala-Sanmartin; Lhousseine Touqui; Marc Chanson; Aleksander Edelman; Mario Ollero
Journal:  PLoS One       Date:  2009-10-22       Impact factor: 3.240

9.  Cytosolic phospholipase A2alpha mediates Pseudomonas aeruginosa LPS-induced airway constriction of CFTR -/- mice.

Authors:  Yong-Zheng Wu; Mohammad Abolhassani; Mario Ollero; Fariel Dif; Naonori Uozumi; Micheline Lagranderie; Takao Shimizu; Michel Chignard; Lhousseine Touqui
Journal:  Respir Res       Date:  2010-04-29

10.  The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung disease.

Authors:  David P Nichols; Assem G Ziady; Samuel L Shank; Jean F Eastman; Pamela B Davis
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-08-21       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.